NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded shares of Sequenom to Neutral, noting the non-invasive prenatal fetal aneuploidy testing firm's announcement of its national contract with the Blue Cross Blue Shield Association last week.

Credit Suisse analyst Vamil Divan upgraded shares of the San Diego-based company's stock from Underperform and raised its target price to $4.50 from a previous target of $4.00.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.